All In Biotech

Drug Trial Radar · NCT02132000

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

Last checked: Nov 19, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 3,036 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,036

Planned (sponsor's estimate)

Start

Apr 2014

Primary completion

May 2020

Study completion May 2020

Sponsor

Lead sponsor
Fengxi SuAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.

Conditions

  • Breast Cancer Patients in Premenopausal
  • Estrogen and/or Progesterone Receptor Positive

Interventions

  • toremifene or tamoxifenDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. survival outcomes: disease free survivalTime frame: up to 5 years
  2. 5-year overall survivalTime frame: up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Breast cancer center of Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.